Dr. Heiner Fritzemeier

Research interests: 
  • Gynecological therapy
  • Drug Discovery
  • Drug Development

Managing Director of the Centre for Medical Biotechnology (ZMB)

CoLab Biomed research keywords: 
Selected publications: 

Weigt C, Hertrampf T, Kluxen FM, Flenker U, Hülsemann F, Fritzemeier KH, Diel P. Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats. Mol Cell Endocrinol. 2013 Sep 5;377(1-2):147-58.

Cleve A, Fritzemeier KH, Haendler B, Heinrich N, Möller C, Schwede W, Wintermantel T. Pharmacology and clinical use of sex steroid hormone receptor modulators. Handb Exp Pharmacol. 2012;(214):543-87.

Arias-Loza PA, Kreissl MC, Kneitz S, Kaiser FR, Israel I, Hu K, Frantz S, Bayer B, Fritzemeier KH, Korach KS, Pelzer T. The estrogen receptor-α is required and sufficient to maintain physiological glucose uptake in the mouse heart. Hypertension. 2012 Oct;60(4):1070-7.

Menning A, Walter A, Rudolph M, Gashaw I, Fritzemeier KH, Roese L. Granulocytes and vascularization regulate uterine bleeding and tissue remodeling in a mouse menstruation model. PLoS One. 2012;7(8):e41800.

Muehlfelder M, Arias-Loza PA, Fritzemeier KH, Pelzer T. Both estrogen receptor subtypes, ERα and ERβ, prevent aldosterone-induced oxidative stress in VSMC via increased NADPH bioavailability. Biochem Biophys Res Commun. 2012 Jul 13;423(4):850-6.

Otto C, Kantner I, Nubbemeyer R, Schkoldow J, Fuchs I, Krahl E, Vonk R, Schüler C, Fritzemeier KH, Erben RG. Estradiol release kinetics determine tissue response in ovariectomized rats. Endocrinology. 2012 Apr;153(4):1725-33.

Velders M, Schleipen B, Fritzemeier KH, Zierau O, Diel P. Selective estrogen receptor-β activation stimulates skeletal muscle growth and regeneration. FASEB J. 2012 May;26(5):1909-20.

Weigt C, Hertrampf T, Zoth N, Fritzemeier KH, Diel P. Impact of estradiol, ER subtype specific agonists and genistein on energy homeostasis in a rat model of nutrition induced obesity. Mol Cell Endocrinol. 2012 Apr 4;351(2):227-38.

Schleipen B, Hertrampf T, Fritzemeier KH, Kluxen FM, Lorenz A, Molzberger A, Velders M, Diel P. ERβ-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis. 2011 Nov;32(11):1675-83.

Velders M, Solzbacher M, Schleipen B, Laudenbach U, Fritzemeier KH, Diel P. Estradiol and genistein antagonize the ovariectomy effects on skeletal muscle myosin heavy chain expression via ER-beta mediated pathways. J Steroid Biochem Mol Biol. 2010 May;120(1):53-9.

Yang YH, Ngo D, Jones M, Simpson E, Fritzemeier KH, Morand EF. Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor alpha. Arthritis Rheum. 2010 Apr;62(4):1017-25.

Otto C, Fuchs I, Vonk R, Fritzemeier KH. Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate. Maturitas. 2010 Apr;65(4):386-91.

Arias-Loza PA, Muehlfelder M, Elmore SA, Maronpot R, Hu K, Blode H, Hegele-Hartung C, Fritzemeier KH, Ertl G, Pelzer T. Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease. Toxicol Pathol. 2009 Dec;37(7):969-82.

Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, Vonk R, Fritzemeier KH. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod. 2009 Jan;80(1):34-41.

Seidlová-Wuttke D, Prelle K, Fritzemeier KH, Wuttke W. Effects of estrogen receptor alpha- and beta-selective substances in the metaphysis of the tibia and on serum parameters of bone and fat tissue metabolism of ovariectomized rats. Bone. 2008 Nov;43(5):849-55.

Patchev VK, Bachurin SO, Albers M, Fritzemeier KH, Papadopoulos V. Neurotrophic estrogens: essential profile and endpoints for drug discovery. Drug Discov Today. 2008 Sep;13(17-18):734-47. Review.

Otto C, Fuchs I, Altmann H, Klewer M, Schwarz G, Bohlmann R, Nguyen D, Zorn L, Vonk R, Prelle K, Osterman T, Malmström C, Fritzemeier KH. In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro. J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):95-100.

Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology. 2008 Oct;149(10):4846-56.

Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Altmann H, Fritzemeier KH. In vivo characterization of progestins with reduced non-genomic activity in vitro. Ernst Schering Found Symp Proc. 2007;(1):151-70. Review.

Hertrampf T, Schleipen B, Velders M, Laudenbach U, Fritzemeier KH, Diel P. Estrogen receptor subtype-specific effects on markers of bone homeostasis. Mol Cell Endocrinol. 2008 Sep 10;291(1-2):104-8.

Otto C, Fuchs I, Altmann H, Klewer M, Walter A, Prelle K, Vonk R, Fritzemeier KH. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology. 2008 Aug;149(8):3952-9. 

Hertrampf T, Seibel J, Laudenbach U, Fritzemeier KH, Diel P. Analysis of the effects of oestrogen receptor alpha (ERalpha)- and ERbeta-selective ligands given in combination to ovariectomized rats. Br J Pharmacol. 2008 Apr;153(7):1432-7. doi: 10.1038/sj.bjp.0707664.

Jazbutyte V, Arias-Loza PA, Hu K, Widder J, Govindaraj V, von Poser-Klein C, Bauersachs J, Fritzemeier KH, Hegele-Hartung C, Neyses L, Ertl G, Pelzer T. Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res. 2008 Mar 1;77(4):774-81.

Otto C, Wessler S, Fritzemeier KH. Exploiting nongenomic estrogen receptor-mediated signaling for the Development of pathway-selective Estrogen receptor ligands. Ernst Schering Found Symp Proc. 2006;(1):163-81. Review.

McPherson SJ, Ellem SJ, Patchev V, Fritzemeier KH, Risbridger GP. The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands. Ernst Schering Found Symp Proc. 2006;(1):131-47. Review.

Arias-Loza PA, Jazbutyte V, Fritzemeier KH, Hegele-Hartung C, Neyses L, Ertl G, Pelzer T. Functional effects and molecular mechanisms of subtype-selective ERalpha and ERbeta agonists in the cardiovascular system. Ernst Schering Found Symp Proc. 2006;(1):87-106. Review.

Wintermantel TM, Elzer J, Herbison AE, Fritzemeier KH, Schütz G. Genetic dissection of estrogen receptor signaling in vivo. Ernst Schering Found Symp Proc. 2006;(1):25-44. Review.

Sumner BE, Grant KE, Rosie R, Hegele-Hartung Ch, Fritzemeier KH, Fink G. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain. Neurosci Lett. 2007 Apr 24;417(1):95-9.

Hertrampf T, Gruca MJ, Seibel J, Laudenbach U, Fritzemeier KH, Diel P. The bone-protective effect of the phytoestrogen genistein is mediated via ER alpha-dependent mechanisms and strongly enhanced by physical activity. Bone. 2007 Jun;40(6):1529-35.

McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 2007 Feb;148(2):566-74.

Toschi L, Hilbig J, Wintermantel T, Engelhaupt A, Walter A, Fritzemeier KH, Hillisch A. Protein-structure-based prediction of animal model suitability for pharmacodynamic studies of subtype-selective estrogens. ChemMedChem. 2006 Nov;1(11):1237-48.

Arias-Loza PA, Hu K, Schäfer A, Bauersachs J, Quaschning T, Galle J, Jazbutyte V, Neyses L, Ertl G, Fritzemeier KH, Hegele-Hartung C, Pelzer T. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension. 2006 Nov;48(5):994-1001.

Jazbutyte V, Hu K, Kruchten P, Bey E, Maier SK, Fritzemeier KH, Prelle K, Hegele-Hartung C, Hartmann RW, Neyses L, Ertl G, Pelzer T. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension. 2006 Oct;48(4):579-86.

Wessler S, Otto C, Wilck N, Stangl V, Fritzemeier KH. Identification of estrogen receptor ligands leading to activation of non-genomic signaling pathways while exhibiting only weak transcriptional activity. J Steroid Biochem Mol Biol. 2006 Jan;98(1):25-35.

Pelzer T, Jazbutyte V, Hu K, Segerer S, Nahrendorf M, Nordbeck P, Bonz AW, Muck J, Fritzemeier KH, Hegele-Hartung C, Ertl G, Neyses L. The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res. 2005 Sep 1;67(4):604-12.

von Langen J, Fritzemeier KH, Diekmann S, Hillisch A. Molecular basis of the interaction specificity between the human glucocorticoid receptor and its endogenous steroid ligand cortisol. Chembiochem. 2005 Jun;6(6):1110-8.

Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Müller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5129-34.

Hillisch A, Peters O, Kosemund D, Müller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol. 2004 Jul;18(7):1599-609.

Centre for Medical Biotechnology (ZMB)
University of Duisburg-Essen
Contact information: 

+49 201 183 3670

Campus Essen
S03 S00 A59